神经干细胞移植治疗阿尔兹海默病的机制研究进展

doi:10.16352/j.issn.1001-6325.2023.07.1148

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1148-1151.doi: 10.16352/j.issn.1001-6325.2023.07.1148

神经干细胞移植治疗阿尔兹海默病的机制研究进展

陈小坤, 包新杰^*, 高俊, 李永宁^*

中国医学科学院北京协和医学院北京协和医院神经外科,北京 100730

收稿日期:2023-04-17 修回日期:2023-05-23 发布日期:2023-07-05
通讯作者: ^*liyongning@pumch.cn; baoxinjie@pumch.cn
基金资助:
国家自然科学基金(82170799, 82171475)

An update on the mechanism of neural stem cell transplantation in the treatment of Alzheimer’s disease

CHEN Xiaokun, BAO Xinjie^*, GAO Jun, LI Yongning^*

Department of Neurosurgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2023-04-17 Revised:2023-05-23 Published:2023-07-05

摘要/Abstract

摘要： 目前并无有效的策略可以减缓阿尔茨海默病(AD)的进展。加深对AD发病机制的理解和研发新的治疗方法至关重要。干细胞移植治疗神经退行性疾病是目前的研究热点。许多研究认为神经干细胞(NSCs)可以分化成功能性神经元,可以替代原有死亡的神经元,并与相邻的残存神经元形成突触连接,从而达到疾病治疗作用。理论上,利用NSCs替换和恢复受损的乙酰胆碱能神经元和突出连接,可能为AD提供新的治疗选择。本文回顾了近期的临床前研究,总结了NSCs移植在AD治疗中的机制进展。

关键词: 阿尔茨海默病, 细胞移植, 神经干细胞

Abstract: At present, no effective strategy exists to slow down the progression of Alzheimer’s disease (AD). A deeper understanding of the pathogenesis of AD and the development of new therapeutic approaches are essential. Stem cell transplantation for the treatment of neurodegenerative diseases is currently a research hotspot. Numerous studies have suggested that neural stem cells (NSCs) can differentiate into functional neurons, replace dead neurons, and form synaptic connections with adjacent surviving neurons, thereby achieving a therapeutic effect. In theory, the use of NSCs to replace and restore damaged cholinergic neurons and synapses may provide a new therapeutic option for AD. This review summarizes the recent preclinical research progress of NSC transplantation for the treatment of AD.

Key words: Alzheimer’s disease, cell transplantation, neural stem cells

中图分类号:

R741.05

陈小坤, 包新杰, 高俊, 李永宁. 神经干细胞移植治疗阿尔兹海默病的机制研究进展[J]. 基础医学与临床, 2023, 43(7): 1148-1151.

CHEN Xiaokun, BAO Xinjie, GAO Jun, LI Yongning. An update on the mechanism of neural stem cell transplantation in the treatment of Alzheimer’s disease[J]. Basic & Clinical Medicine, 2023, 43(7): 1148-1151.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.07.1148

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I7/1148

参考文献

[1] Long JM, Holtzman DM.Alzheimer disease: an update on pathobiology and treatment strategies[J]. Cell, 2019, 179: 312-339.
[2] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease[J]. Lancet, 2021, 397: 1577-1590.
[3] Liu XY, Yang LP, Zhao L.Stem cell therapy for Alzheimer’s disease[J]. World J Stem Cells, 2020, 12: 787-802.
[4] DE Strooper B, Karran E.The cellular phase of Alzheimer’s disease[J]. Cell, 2016, 164: 603-615.
[5] Cribbs DH, Berchtold NC, Perreau V, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study[J]. J Neuroinflammation, 2012, 9: 179. doi:10.1186/1742-2094-9-179.
[6] Macdonald R, Barnes K, Hastings C, et al. Mitochondrial abnormalities in Parkinson’s disease and Alzheimer’s disease: can mitochondria be targeted therapeutically?[J]. Biochem Soc Trans, 2018, 46: 891-909.
[7] Wingo AP, Liu Y, Gerasimov ES, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis[J]. Nat Genet, 2021, 53: 143-146.
[8] Yan S, Zheng C, Paranjpe MD, et al. Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer’s disease[J]. Theranostics, 2020, 10: 10563-10572.
[9] Rasmussen KL, Nordestgaard BG, Frikke-schmidt R, et al. An updated Alzheimer hypothesis: complement c3 and risk of Alzheimer’s disease-a cohort study of 95,442 individuals[J]. Alzheimers Dement, 2018, 14: 1589-1601.
[10] Lim YY, Kalinowski P, PietrzakI RH, et al. Association of β-amyloid and apolipoprotein eε4 with memory decline in preclinical Alzheimer aisease[J]. JAMA Neurol, 2018, 75: 488-494.
[11] Sung PS, Lin PY, Liu CH, et al. Neuroinflammation and neurogenesis in Alzheimer’s disease and potential therapeutic approaches[J]. Int J Mol Sci, 2020, 21:701. doi:10.3390/ijms21030701.
[12] Serrano-pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021, 20: 68-80.
[13] Madrazo I, Kopyov O, Avila-Rodriguez MA, et al. Transplantation of human neural progenitor cells (NPC) into putamina of parkinsonian patients: a case series study, safety and efficacy four years after surgery[J]. Cell Transplant, 2019, 28: 269-285.
[14] Boese AC, Hamblin MH, Lee JP.Neural stem cell therapy for neurovascular injury in Alzheimer’s disease[J]. Exp Neurol, 2020, 324: 113112. doi:10.1016/j.expneurol.2019.113112.
[15] Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction[J]. Nat Med, 2019, 25: 270-276.
[16] Zhang Q, Wu HH, Wang Y, et al. Neural stem cell transplantation decreases neuroinflammation in a transgenic mouse model of Alzheimer’s disease[J]. J Neurochem, 2016, 136: 815-825.
[17] Kim JA, Ha S, Shin KY, et al. Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer’s disease mouse model[J]. Cell Death Dis, 2015, 6: e1789. doi:10.1038/cddis.2015.138.
[18] Moreno-Jimenez EP, Flor-garcia M, Terreros-Roncal J, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease[J]. Nat Med, 2019, 25: 554-560.
[19] Sorrells SF, Paredes MF, Cebrian-Silla A, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults[J]. Nature, 2018, 555: 377-381.
[20] Boldrini M, Fulmore CA, Tartt AN, et al. Human hippocampal neurogenesis persists throughout aging[J]. Cell Stem Cell, 2018, 22: 589-599.
[21] Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease[J]. Proc Natl Acad Sci U S A, 2009, 106: 13594-13599.

神经干细胞移植治疗阿尔兹海默病的机制研究进展

An update on the mechanism of neural stem cell transplantation in the treatment of Alzheimer’s disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘诗雨, 刘宇健. 组织激肽释放酶8在神经系统疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 660-664.
[2]	周梦杰, 孙倩倩, 于洋. BEND6过表达对小鼠神经干细胞基因转录表达的影响[J]. 基础医学与临床, 2023, 43(2): 246-251.
[3]	王远卓, 郑清月, 张翰林, 仇文颖, 王涛, 马超. 小胶质细胞在阿尔茨海默病神经炎性反应中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1310-1313.
[4]	徐娟, 李晔. 铁死亡在阿尔茨海默病中作用的研究进展[J]. 基础医学与临床, 2022, 42(7): 1129-1133.
[5]	武坤, 聂波, 李云涛, 杨金荣, 程沈菊, 李艳红, 史明霞. 外周血miR-200c水平对移植异基因造血干细胞后急性移植物抗宿主病发生的预测作用[J]. 基础医学与临床, 2022, 42(6): 871-875.
[6]	路亚岚, 周澧, 韩云林, 王克维, 秦川. 冈田酸诱导人神经母细胞瘤细胞系SH-SY5Y损伤[J]. 基础医学与临床, 2022, 42(6): 927-932.
[7]	沈杰, 严洁, 钟明, 庞睿娟, 罗永杰. LncRNA SNHG14调控miR-142-5p对寡聚态Aβ诱导的鼠源神经细胞系PC12损伤的影响[J]. 基础医学与临床, 2022, 42(6): 913-919.
[8]	孙健茹, 仇文颖, 钱晓菁, 马超. Fc-gamma Ⅰ型受体在阿尔茨海默病患者和模型小鼠脑皮质的表达[J]. 基础医学与临床, 2022, 42(5): 740-744.
[9]	梁国新, 梁茵茹, 刘淑贤, 陈康振, 林勇, 秦江霞, 吴洪福. PF-127-LV-NTFs三维复合支架培养大鼠神经干细胞[J]. 基础医学与临床, 2022, 42(1): 75-81.
[10]	房婷, 李响, 刘洁, 王皓. 鼠李糖乳杆菌通过调节肠道微生物群缓解造血干细胞移植后肝脏移植物抗宿主病[J]. 基础医学与临床, 2021, 41(9): 1303-1308.
[11]	孙静瑶, 佟伟民, 牛亚梅. mRNA转录后调控异常在阿尔茨海默病发病机制中的研究进展[J]. 基础医学与临床, 2021, 41(5): 749-752.
[12]	孙添怡, 刘帆, 仇文颖, 马超. piRNAs在阿尔茨海默病患者脑中的差异表达[J]. 基础医学与临床, 2021, 41(4): 533-538.
[13]	王紫涵, 罗金定, 田英入, 奉水东, 凌宏艳. 小胶质细胞引起和促进阿尔茨海默病的研究进展[J]. 基础医学与临床, 2021, 41(2): 277-281.
[14]	刁华琼, 李小黎, 林亮吟, 刘海鹏, 陈弘婧, 丁海月, 魏丹. 外泌体microRNAs与阿尔茨海默病关系的研究进展[J]. 基础医学与临床, 2020, 40(11): 1542-1545.
[15]	曾利敏, 鲁召辉, 周丽平, 朱超霞. 甲基莲心碱通过调控miR-29a-3p/AQP4表达抑制Aβ1-42致PC12细胞的损伤[J]. 基础医学与临床, 2020, 40(1): 83-91.